Layoffs
Filter News
Found 166 articles
-
Based in South San Francisco, Five Prime Therapeutics announced that as part of a restructuring program, it will eliminate 41 current jobs, or about 20 percent of its current headcount. The positions cut will be mostly in areas related to research, pathology and manufacturing. The company expects...
-
After conducting a routine research-and-development review, Pfizer is easing away from preclinical biosimilar development. The bottom line is the company is ending five preclinical programs in its biosimilar area and cutting 150 positions.
-
Your Feedback Matters! Topics in 2019
1/15/2019
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about. -
AstraZeneca has indicated it plans to lay off 210 people in Boulder and Longmont. The reason is the company is consolidating “the biologics manufacturing network in one large-scale drug substance facility” in Frederick, Maryland.
-
Over the past decade, BMS has been no stranger to flexing its M&A muscle. The company made numerous focused-acquisitions that have positioned itself as a leader in oncology. BMS CEO Giovanni Caforio noted that the massive deal for Celgene is another piece to that puzzle.
-
Selecta Biosciences announced that as part of restructuring efforts it is cutting its current workforce by 36 percent. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent.
-
Traditionally, Genentech has tended to operate with less hands-on scrutiny from the business bean counters at its Swiss Roche headquarters. These more recent job cuts suggest those days may be over.
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more. -
More pharma workers in France are receiving coal in their stockings this year after Germany-based Boehringer Ingelheim announced plans to cut about 300 jobs in that country as part of a reorganization of its operations in France.
-
Sanofi to Cut 670 Jobs in France by 2020
12/6/2018
Some French employees of drug giant Sanofi will receive an unwanted Christmas present this year – pink slips. The company will lay off 670 employees in France on what has been reported as a “voluntary basis.” -
Georgia-based MiMedx has been dealing with continued fallout from questions over its earnings and sales practices.
-
Bayer will cut 12,000 jobs as it prepares an overhaul of its business that includes exiting its animal health business as it deals with the fallout from its $63 billion acquisition of Monsanto. Additionally, the company said it will sell its 60 percent stake in Germany-based site services provide...
-
Abeona did not specify the type of misconduct that Carsten Thiel engaged in, but it was serious enough to warrant termination.
-
Boston Scientific's restructuring will take place over a three-year period. The company expects it overall employee base to remain relatively unchanged when it is complete, although some losses are expected.
-
Theranos fit in with the opaque culture of Silicon Valley, which allowed it to thrive and amass a fortune without delivering anything, book argues.
-
In the wake of a Complete Response Letter issued by the FDA, Trevana, Inc. is slashing one-third of its workforce. On Wednesday, Merrimack Pharmaceuticals also announced it was terminating 60 percent of its staff as the company narrows its research and development focus.
-
Shares of South San Francisco-based Achaogen, Inc. fell more than 12 percent in Monday trading after the company signaled that it began a review of strategic alternatives that could include a sale of the company.
-
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the c...
-
Citing structural simplification, Pfizer announced it plans to cut its global staffing by about 2 percent. It expects to do so primarily through voluntary layoffs and early retirement through the end of this year and early in 2019.
-
Cesca Therapeutics Announces Cost Reduction Measures Aimed at Achieving Cash Flow Positive Position in 2019
10/16/2018
Cesca Therapeutics (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, announced today the departure of Vivian Liu, Chief Operating Officer, and Joseph Balagot, Senior Vice President of Corporate Development, and one other member of the managerial team.